Approach to the child with fractures

J Clin Endocrinol Metab. 2011 Jul;96(7):1943-52. doi: 10.1210/jc.2010-2546.

Abstract

Evaluation of the child with fractures is challenging, as no clear guidelines exist to distinguish traumatic from pathological fractures. Although most fractures in childhood are benign, recurrent fractures may be associated with a wide variety of primary skeletal diseases as well as secondary causes, necessitating a careful history and physical exam to guide the evaluation. There is no "gold standard" for the evaluation and treatment of children with fractures and low bone mineral density (BMD); therefore, the diagnosis of osteoporosis in a pediatric patient should be made using a combination of clinical and radiographic features. Interpretation of bone densitometry in growing patients presents a unique set of challenges because areal BMD measured by dual-energy x-ray absorptiometry depends on multiple dynamic variables. Interpretation of pediatric dual-energy x-ray absorptiometry should be based on Z-scores (sd scores compared to age, sex, and ethnicity-matched controls), using normative databases specific to the brand of densitometer and the patient population. Given the skeleton's ability to recover from low BMD through modeling and remodeling, optimizing management of underlying conditions leading to bone fragility is the initial step. Conservative measures including calcium and vitamin D supplementation and weight-bearing physical activity are important interventions that should not be overlooked. The use of bisphosphonates in children and adolescents is controversial due to lack of long-term efficacy and safety data and should be limited to clinical trials and compassionate therapy in children with significantly compromised quality of life. Close monitoring is required, and further study is necessary to assess their long-term safety and efficacy in children.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Absorptiometry, Photon
  • Bone Density / drug effects*
  • Bone Density Conservation Agents / pharmacology
  • Bone Density Conservation Agents / therapeutic use
  • Child
  • Diphosphonates / pharmacology
  • Diphosphonates / therapeutic use
  • Female
  • Fractures, Bone / drug therapy
  • Fractures, Bone / etiology*
  • Humans
  • Osteoporosis / complications*
  • Osteoporosis / drug therapy
  • Pamidronate

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Pamidronate